DGAP-News: PAION ANNOUNCES INITIATION OF US PHASE III

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: PAION ANNOUNCES INITIATION OF US PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY

DGAP-News: PAION AG / Key word(s): Research Update PAION ANNOUNCES INITIATION OF US PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY 31.03.2015 / 13:00 --------------------------------------------------------------------- PAION ANNOUNCES INITIATION OF U.S. PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY - Remimazolam's U.S. Phase III program to include two pivotal trials and one smaller safety trial launching in 2015 - Patient recruitment for Phase III in colonoscopy is expected to complete before end of 2015 Aachen, 31 March 2015 - PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announced the initiation of a U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy. During Phase II clinical trials, Remimazolam displayed faster onset of sedation and greater procedural success compared to midazolam. Remimazolam showed a benign safety profile and patients experienced rapid recovery from sedation including faster recovery of cognitive function as compared to midazolam. The initiation of the Phase III trial in patients undergoing colonoscopies marks the start of PAION's Phase III clinical program, which includes a second pivotal Phase III trial in patients undergoing bronchoscopies and a third smaller safety trial in high-risk patients undergoing colonoscopies. In parallel, PAION will conduct three Phase I studies. Wolfgang Söhngen, M.D., Ph.D., chief executive officer of PAION AG, said: "The initiation of the Phase III trial in patients undergoing colonoscopy is an important milestone for PAION. We expect the current study to further confirm Phase II data that showed Remimazolam was safe and highly effective in providing procedural sedation. Midazolam has been selected as a comparator because PAION aims to get a label similar to Midazolam." Greg Papaz, president and chief executive officer of PAION, Inc., added: "The change in the reimbursement of colonoscopies in the U.S. underscores the medical need for an alternative sedation agent. We expect Remimazolam to compete with the safest prescribed sedatives and enable high-patient throughput with a fast onset/rapid recovery, a profile currently unmet in the anesthetic space." This Phase III clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled, U.S. multicenter study in 460 patients undergoing colonoscopies for diagnostic or therapeutic reasons. Patients will be randomized to receive Remimazolam, midazolam or placebo in addition to fentanyl to achieve moderate sedation. The primary objective of this study is to investigate the short-term sedation, and hence the success of a colonoscopy compared to placebo and midazolam. The primary endpoint is the successful completion of the colonoscopy procedure with no requirement for alternative sedative. The completion of patient recruitment is expected before the end of 2015. ### About Remimazolam Remimazolam is an innovative ultra-short-acting general sedative/anesthetic. As a result of its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anesthesia compounds. Remimazolam's rapid offset is a consequence of its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam has potential in three indications: - Procedural sedation (Lead indication U.S.) - General anesthesia (Lead indication EU, Japan) - ICU sedation (Phase II Japan) Remimazolam is available for licensing outside China, Russia (CIS) Turkey, MENA Region, South Korea and Canada, where the compound is partnered with Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm. About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, U.S. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. Remimazolam is the building block for its future marketing activities. For more information please visit www.paion.com PAION Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------- 31.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 339335 31.03.2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 182

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 121

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 105

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 104

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 98

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 97

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 299

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading
Minerals Technologies Showcases Innovative PFAS Solutions at Symposium

Updated Category News Views 185

Minerals Technologies to Present at Gabelli Funds PFAS Symposium Minerals Technologies Inc. (MTI) is thrilled to announce its participation in the upcoming PFAS Symposium hosted by Gabelli Funds. This notable event is set to take place in New York City, bringing together key figures in the industry to discuss significant advancements and novel strategies for tackling...

Continue Reading
Morning Market Insights for Key Stocks: A Daily Review

Updated Category News Views 338

Daily Market Insights: Leading Stocks to Watch Good morning, traders. Today’s notes zero in on SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA—names that tend to steer the broader tape. Our read on price comes from a blend of key levels shaped by price action, trading volume, and options flow. We refresh these levels daily and share them with Market Clubhouse...

Continue Reading
Exploring the Evolving Landscape of Electric Vehicles in the U.S.

Updated Category News Views 224

The Current State of Electric Vehicles in the U.S. The electric vehicle (EV) landscape in the U.S. is experiencing transformative changes. As the country marks significant milestones in EV deployment, there are noteworthy gaps in infrastructure and consumer attitudes that need addressing. The third annual HERE-SBD EV Index reveals how far the U.S. has come, yet highlights...

Continue Reading
eBay's Legal Victory: Dismissal of Harmful Product Claims

Updated Category News Views 173

eBay's legal drama hit the news when the U.S. government slammed them with a lawsuit accusing the online giant of violating the Clean Air Act back in 2024. The crux? Selling products that supposedly helped folks skirt around those pesky auto pollution controls. You know how it is—desks buzzing about regulatory risks, and traders getting twitchy over such moves. The...

Continue Reading